Pericardial and pleural effusions associated with sirolimus and discussion of possible mechanisms by Rocha, S. et al.
Port J Nephrol Hypert 2012; 26(2): 165-169    165
CMYKP
ABSTRACT 
Sirolimus, a mammalian target of rapamycin 
inhibitor, is an increasingly used immunosuppres-
sant in solid-organ transplantation. There are an 
increasing number of reports of unusual oedema-
tous adverse effects associated with this drug, 
including lymphoedema, ascites and pleural effu-
sions, and a few reports of pericardial effusions. 
No pathophysiological explanation for these phe-
nomena has been disclosed.
We report a 33-year-old sirolimus-treated kidney 
transplant recipient with chronic pericardial and pleu-
ral effusions identified nine years after transplanta-
tion. He was initially treated for a presumed tuber-
culous pericarditis, even though cultures for 
Mycobacterium tuberculosis were negative. After 12 
months of antitubercular therapy, visceral effusions 
persisted. Pericardial effusion was drained and sta-
bilised. After exclusion of other causes, sirolimus 
toxicity was considered the most likely cause. Two 
months after discontinuation of sirolimus, visceral 
effusions disappeared.
Interaction of mammalian target of rapamycin 
inhibitors with mediators of lymphangiogenesis may 
be a common link in oedematous states associated 
with sirolimus.
Key-Words:
Immunosuppression; kidney transplantation; lymp-
hangiogenesis; mTOR inhibitors; rapamycin; 
serositis.
INTRODUCTION 
Sirolimus is a macrolide antibiotic used for pro-
phylaxis of rejection in patients who have received 
solid-organ transplants.
Common side effects of sirolimus include dys-
lipidaemia, proteinuria, anaemia, thrombocytope-
nia, decreased wound healing, oral ulcers and 
lymphoceles. There have been an increasing num-
ber of reports of other rarer complications of siroli-
mus, including interstitial pneumonitis, pulmonary 
alveolar proteinosis1, lymphoedaema2-7, chylous 
ascites8, and pericardial effusions6,9-11. The mecha-
nisms of these adverse reactions have not been 
fully elucidated. In 2008, a pharmacovigilance 
review11 suggested a possible association between 
sirolimus and the occurrence of pericardial effu-
sion, most notably in cardiac transplant recipients. 
In kidney transplant recipients we are aware of 
two reports of pericardial effusion associated with 
sirolimus6,10.
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We report a kidney transplant recipient for nine 
years with chronic pleural and pericardial effusions, 
which we believe were attributed to sirolimus. The 
anti-lymphangiogenic activity of mTOR inhibition may 
be a common denominator in the pathophysiology 
of oedematous states associated with sirolimus.
CASE REPORT 
A 33-year-old male with a status of post-deceased 
donor kidney transplant 12 years prior was admitted 
to our department with fever and chronic pericardial 
and pleural effusions.
In 1994, at the age of 17 years, hypertension and 
advanced chronic kidney disease was diagnosed, 
presumed to be due to chronic glomerulonephritis. 
Two years later he started haemodialysis.
In 1998, he received a kidney transplant from a 
deceased-donor. Induction of immunosuppression 
consisted of sirolimus, ciclosporin and steroids as 
part of a study protocol12. He had immediate graft 
function and was discharged with a serum creatinine 
of 1.8 mg/dL. His wound healing was unremarkable, 
and kidney function remained stable with a serum 
creatinine around 1.5 mg/dL.
In 2005, his serum creatinine increased to 2.5 mg/
dL and he developed proteinuria (1 g/day). Ciclosporin 
was suspended and he maintained sirolimus (trough 
levels 6-8 ng/mL) and prednisolone. Renal allograft 
function slightly improved and remained stable with 
serum creatinine around 2.0 mg/dL and proteinuria 
1 g/day. In 2006, a chest X-ray shown an increased 
cardiac silhouette, attributed to left ventricular 
hypertrophy.
In 2007, he was admitted to our department with 
fever and dry cough lasting for a week. His temperature 
was 38.2ºC and blood pressure 141/91 mmHg. Arterial 
blood gases (FiO2: 21%) pO2: 65 mmHg. Laboratory 
findings revealed a CRP of 200 mg/L, a serum crea-
tinine of 2.4 mg/dL and a sirolimus level of 6.3 ng/
mL. Chest X-ray showed bilateral pleural effusions, 
more pronounced on the right. He started levofloxacin 
and cefotaxime to treat a community-acquired pneu-
monia. After 72 hours of therapy, fever persisted, and 
a CT scan was performed to rule out infectious 
complications, namely empyema and lung abscess. A 
right inferior lobe lung condensation, small bilateral 
pleural effusions and a moderate-large pericardial 
effusion were identified (Fig. 1); there were no signs 
of interstitial pneumonitis. Transthoracic echocardio-
gram did not show pericardial tamponade or ventricu-
lar systolic dysfunction. Levofloxacin and cefotaxime 
were maintained until the patient underwent bron-
choscopy, which ruled out Pneumocystis jiroveci, other 
opportunistic infections and lymphocytic alveolitis. 
Mycobacterium tuberculosis culture of bronchoalveolar 
lavage was negative. Serologic studies for virus and 
parasites were negative. Because there were no signs 
of pericardial tamponade and the diagnostic yield was 
low, we did not undertake pericardiocentesis. A pre-
sumptive diagnosis of tuberculous pericarditis and 
pleuritis was made, and anti-tubercular therapy was 
started with three drugs: isoniazid, rifampicin and 
pyrazinamide. Fever disappeared after five days of 
added anti-tubercular therapy, and therapy was main-
tained for 12 months. His immunological study and 
thyroid function were normal. Visceral effusions per-
sisted and were considered most likely idiopathic. 
The patient did not report chest pain and had no 
other signs of fluid overload. His serum creatinine 
remained stable at around 2.0-2.5 mg/dL.
In 2009, even though there were no signs of hae-
modynamic disturbances aggravating clinical evolution, 
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Figure 1
Thoracic CT scan showing bilateral pleural effusions more pronounced on 
the right side, with lower inferior lobe lung consolidation, and a moderate-
large volume pericardial effusion.
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an elective pericardiocentesis was undertaken, due to 
the risk of sudden cardiac tamponade. The procedure 
was complicated by right ventricle laceration and car-
diac tamponade. He underwent surgical drainage of 
the pericardial effusion and pericardial window and 
biopsy. Pericardial fluid was a sterile exudate without 
malignant cells; adenosine deaminase (ADA) was 17 
U/L (N< 22 U/L); PCR for Mycobacterium tuberculosis 
was negative. Pericardial biopsy revealed pericardial 
fibrosis and mesothelial hyperplasia, without malignant 
cells. The patient was discharged with a serum crea-
tinine of 3.3 mg/dL. Further echocardiogram showed 
a small pericardial effusion.
Two months later, he was readmitted with fever 
and aggravated pleural effusions. He referred fever 
and dry cough lasting for three days. Laboratory data 
revealed CRP 280 mg/L, serum creatinine 3.9 mg/dL, 
and sirolimus 6.7 ng/mL. CT scan showed a volume 
increase of pleural effusions, with no abnormal lung 
findings. Echocardiogram findings showed a small 
volume pericardial effusion, with no signs of cardiac 
tamponade. Thoracocentesis revealed a sterile exu-
date with negative ADA. Due to presumed community-
acquired respiratory infection, we started levofloxa-
cin, and fever disappeared 48 hours later. Without 
any other obvious aetiology for the chronic effusions, 
sirolimus was considered the most likely cause, and 
was replaced by mofetil mycophenolate.
Two months after sirolimus discontinuation, pleu-
ral and pericardial effusions had completely regressed. 
The patient did not receive any other specific treat-
ment, including diuretics. At 10 months of follow-up, 
repeat chest X-ray was clear and echocardiogram 
showed no pericardial effusion. His kidney allograft 
function improved (serum creatinine 2.7 mg/dL), as 
did proteinuria (1.2 g/day) and anaemia (Hb: 13 g/
dL, without erythropoiesis stimulating agents).
DISCUSSION 
We report a kidney transplant recipient under 
sirolimus with chronic pericardial and pleural effu-
sions. We considered sirolimus the most likely cause 
of these phenomena.
The diagnosis of drug-related toxicity is usually 
suggested by the presence of the following criteria: 
(i) exposition to the drug precedes the occurrence 
of signs and/or symptoms (ii) there is no alternative 
cause for the associated syndrome and (iii) with-
drawal of the drug leads to resolution of the signs 
and/or symptoms.
Nine years after the kidney transplant, our patient 
presented a febrile episode associated with respira-
tory complaints; a lung condensation that failed to 
respond to empiric therapy with levofloxacin. This 
led us to undertake a CT scan to rule out infectious 
complications. A moderate-large pericardial effusion 
and bilateral pleural effusions were disclosed. Due 
to the size of the pericardial effusion and the absence 
of cardiac tamponade, we presumed that the effusion 
was slowly progressive. Chronic effusive pericarditis 
has a broad range of differential diagnosis including 
infectious, immunological, neoplastic, endocrine, 
idiopathic and drug-related causes. In this case, there 
was no previous history of viral infection or acute 
pericarditis, and serologic tests were negative. Hypo-
thyroidism, neoplasm and immunological diseases 
were ruled out, and uraemia seemed a very unlikely 
cause, as the patient’s creatinine clearance was over 
30 ml/min. Tuberculosis seemed the most likely diag-
nosis, even though the cultures for Mycobacterium 
tuberculosis were negative. The incidence of tuber-
culosis in Portugal is quite high13, and solid-organ 
transplant recipients have a marked increase in its 
frequency and severity compared to the general 
population. Persistence of visceral effusions after 
adequate treatment of tuberculosis led us to consider 
sirolimus as a potential causal agent. After reviewing 
the literature, we found an increasing number of 
reports of adverse oedematous events attributed to 
sirolimus.
Lymphoceles are well-described adverse events 
of sirolimus, with an incidence of up to 38%14. They 
result from lesions to the lymphatic network by sur-
gical procedures, trauma, infection or chronic inflam-
mation. In addition to lymphoceles, cases of uni- or 
bilateral eyelid oedema15 and lymphoedema2-7 have 
also been reported. We are aware of 19 reports of 
lymphoedema associated with sirolimus, either loca-
lised2-5,7 or generalised6. De Bartolomeis et al.6 
reported a kidney transplant recipient who developed 
incapacitating generalised lymphoedema, ascites, and 
pleural and pericardial effusions. Three months after 
sirolimus discontinuation, lymphoedema and visceral 
effusions resolved completely. Our group has 
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described a kidney transplant recipient who devel-
oped chylous ascites unrelated to surgical injury one 
year after conversion to sirolimus8. After exclusion 
of other causes, sirolimus was considered the most 
likely aetiology of ascites. One month after sirolimus 
withdrawal, ascites disappeared and did not recur.
In 2004, Montalbano et al.9 described four cases 
of pericardial effusion in sirolimus-treated liver trans-
plant recipients. Three of these patients also had 
pleural effusions. A workup of infectious causes was 
undertaken and was negative. All the patients had 
resolution of visceral effusions after sirolimus dis-
continuation. In 2005, Truong et al.10 described for 
the first time the occurrence of a pericardial effusion 
requiring pericardiocentesis in a sirolimus-treated 
paediatric kidney transplant recipient. Although the 
patient had intercurrent adenoviral infection, siroli-
mus was considered the most likely cause of peri-
cardial effusion. After sirolimus dose reduction, peri-
cardial effusion stabilised and did not recur. In 2008, 
a pharmacovigilance review11 identified 56 cases (35 
in kidney transplant recipients) of pericardial effusion 
coincident with sirolimus therapy, regardless of co-
existence of other possible causes (i.e. cardiac trau-
ma, and viral or drug-induced pericarditis). In cardiac 
transplant recipients under sirolimus, the risk of 
pericardial effusion was substantially higher when 
compared to patients under azathioprin (28% vs. 
9%, P=0.014). In kidney transplant recipients, the 
incidence of pericardial effusion was 0.7-2.3%, with 
a median time to onset of 38 weeks (range 3-202 
weeks) from grafting. They found no differences in 
the incidence of pericardial effusion between patients 
treated de novo or patients converted to sirolimus, 
nor did they mention any correlation of this adverse 
effect to sirolimus blood concentration. The incidence 
of cardiac tamponade was 6.6%, and approximately 
half (31 of 56) of the patients required pericardial 
drainage. They concluded that the available literature 
suggests a possible association between sirolimus-
containing immunosuppressant regimens and the 
occurrence of pericardial effusion, most remarkably 
in cardiac transplant recipients.
Sirolimus-related oedematous adverse events may 
share a common link. The lymphatic network is 
responsible for the interstitial fluid balance and clear-
ance of macromolecules and represents an important 
route for circulation of immune cells, as well as for 
metastatic tumour cells. Under pathological conditions 
such as trauma, surgical disruption, infection, chronic 
inflammation and cancer, there is lymphatic vessel 
proliferation through stimulation of various growth 
factors, including vascular endothelial growth factor 
(VEGF) C and D, acting via VEGF receptor 3 (VEGFR-3). 
Mutated variants of this receptor are responsible for 
congenital lymphoedemas. In 2007, Hubert et al.16 
investigated whether mTOR inhibition, in addition to 
its antihemangiogenic effect, also impedes regenera-
tive lymphangiogenesis. In a murin skin flap model, 
sirolimus impaired the growth of lymphatic endothelial 
cells and lymphatic regenerations in surgical incisions, 
resulting in prolonged macroscopic oedema. Even 
concentrations of sirolimus as low as 1 ng/mL inhibited 
VEGF-C driven proliferation and migration of lymphatic 
endothelial cells. The inhibitory effect of sirolimus on 
VEGF-C expression was also shown in a metastasis 
animal model, in which the number and area of lym-
phatic vessels in primary tumors were significantly 
decreased by this drug17.
These data provide a possible explanation for 
some of the reported adverse effects of sirolimus, 
including impaired wound healing, lymphoceles, lym-
phoedema and visceral effusions. They are also a 
rationale for the use of this drug in certain patho-
logical conditions, such as some types of cancer and 
lymphangiomiomatosis, a rare systemic disease in 
which there is over-expression of VEGF-C18.
Despite the increasing number of reports of 
oedematous effects (peripheral and visceral) associ-
ated with sirolimus, their incidence is very low, sug-
gesting multifactorial mechanisms. Lymphatic insuf-
ficiency induced by surgical trauma, infection and 
inflammation can partly explain the occurrence of 
these phenomena. It is possible that genetic sus-
ceptibility and a pre-existing constitutive lymphatic 
insufficiency contribute to the development of these 
complications in sirolimus-treated patients.
In this case, the mechanisms by which visceral 
effusions occurred remain obscure, as we could not 
identify any preceding traumatic, infectious or inflam-
matory event. We also do not know exactly how 
long after the introduction of sirolimus the visceral 
effusions occurred, since they were incidental find-
ings nine years after grafting. In other reports, visceral 
effusions occurred earlier after introduction of siroli-
mus (maximum five years11). We cannot say with 
absolute certainty whether our patient’s visceral 
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effusions were causally related to sirolimus. However, 
we cannot find alternative explanations for these 
phenomena, and there was clearly a time relationship 
between suspension of sirolimus and their complete 
resolution.
We conclude that, after exclusion of other causes, 
sirolimus should be considered a potential cause of 
visceral effusions. Inhibition of lymphangiogenesis 
is a putative mechanism for this association.
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